Treatment of adult patients with unresectable or metastatic well-differentiated extra-pancreatic (epNETs) and pancreatic (pNETs) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues (SSAs).
As monotherapy for the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).
As monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
As monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.
in combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults
Adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.Adults with advanced RET fusion-positive thyroid cancer (TC) who require systemic therapy following prior treatment with lenvatinib and/or sorafenib.
treatment of advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk per IMDC criteria
No medicines have been found.
